# Clinical Trials Data KRAS - Document 15

# S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01693419

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Pathologically confirmed locally advanced unresectable, recurrent or metastatic adenocarcinoma of pancreas (Stage III-IV ; TNM staging system)\n\* Measurable or evaluable disease by RECIST criteria 1.1\n\* Minimum age of 18 years\n\* ECOG Performance status 0-1\n\* Prior adjuvant chemotherapy without gemcitabine, erlotinib or S-1 is allowed if more than 4 weeks elapsed since completion of chemotherapy.\n\* More than 4 weeks since completion of prior radiotherapy (measurable or evaluable lesions should be outside the radiation field)\n\* Adequate organ functions\n\* Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital.\n\nExclusion Criteria:\n\n\* Patients treated previously with gemcitabine, erlotinib, or S-1 as adjuvant chemotherapy.\n\* Patients with CNS metastases\n\* Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 6 months, pregnancy, or breast feeding\n\* Any previous or concurrent malignancy other than non-melanoma skin cancer or in situ cancer of uterine cervix\n\* Known history of cerebral or leptomeningeal metastases or neurologic disease",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention KRAS mutation status as either an inclusion or exclusion criterion. Therefore, having a KRAS mutation \*would not automatically exclude\* a patient from this trial. They would need to meet all other inclusion criteria and not meet any exclusion criteria to be eligible.